Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 1,600.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,971,894 shares of the company's stock after acquiring an additional 1,855,907 shares during the period. Geode Capital Management LLC owned 105.45% of Tonix Pharmaceuticals worth $650,000 at the end of the most recent reporting period.

Separately, Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $40,000. Hedge funds and other institutional investors own 82.26% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TNXP. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a "sell" rating on the stock. Noble Financial restated an "outperform" rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Stock Down 3.6 %

Tonix Pharmaceuticals stock traded down $0.70 during midday trading on Tuesday, hitting $18.88. 519,043 shares of the company were exchanged, compared to its average volume of 794,625. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The company's fifty day moving average price is $17.31 and its 200-day moving average price is $20.69. The company has a market cap of $121.49 million, a PE ratio of 0.00 and a beta of 1.63.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share for the quarter, missing analysts' consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.20 million. On average, research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.